For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Addition of Noven Boosts Sales: Hisamitsu
January 17, 2011
- AnGes MG Granted Patent for NFκB Decoy Oligo
January 17, 2011
- Korosho to Accelerate Elimination of Drug-Lag: PS Okamoto
January 17, 2011
- JPA Opposed to Unification of Basic Dispensing Fees
January 17, 2011
- Korosho Considering PAL Amendment in 2012: Mr Masugi
January 17, 2011
- Korosho to Enhance Measures against ifestyle Diseases, Cancer, New-Types of Influenza
January 17, 2011
- Premium for New Drug Development Effective for Solving Drug-Lag Problem: MED Director
January 17, 2011
- Safety Measures for Incretin-Related Drugs Insufficient: Medwatcher Japan
January 17, 2011
- Wholesalers' Services Cost-Effective in Japan: FJPWA Report
January 10, 2011
- FDA Approves Merck's Gardasil for Anal Cancer
January 10, 2011
- Prospects for Simultaneous Global Development: 2
January 10, 2011
- Effective Corporate Tax Rate Down 5%, Max R&D Tax Break Rate Down to 20%
January 10, 2011
- CHMP Issues Positive Opinion for Taiho's TS-1
January 10, 2011
- Hope Is Not a Recruiting Strategy
January 10, 2011
- New Drugs Stimulate Osteoporosis Market: M3 Survey
January 10, 2011
- FDA Requests Additional Analytical Data for Ticagrelor
January 10, 2011
- Nippon Kayaku to Start Clinical Studies for Antibody Biosimilars in 2011
January 10, 2011
- MTPC Licenses Bepotastine to Dong-A of South Korea
January 10, 2011
- Small Pharmacy Operators to Create Their Own Association
January 10, 2011
- Taiyo Not to Reduce No. of Products It Manufactures
January 10, 2011
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…